Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315), a global biotech firm focused on groundbreaking antibody therapeutics, has revealed an Exclusive Option and License Agreement with Radiance Biopharma Inc., a biotech company specializing in the development of next-gen Antibody Drug Conjugates.

This agreement grants Radiance the option to license a first-of-its-kind fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) from Biocytogen. This license covers therapeutic product development, manufacturing, and global commercialization for all human indications. HER2 and TROP2 are tumor-associated antigens found in various cancers, including breast, gastric, colorectal, bladder, pancreatic, and non-small-cell lung cancer.

As outlined in the agreement, should Radiance exercise the option, Biocytogen stands to receive an option fee, licensing fee, development and commercialization milestone payments, and single-digit royalties on net sales. Additionally, Biocytogen holds the right to share sublicensing fees between Radiance and third parties.

Dr. Yuelei Shen, President and CEO of Biocytogen, expressed enthusiasm for the collaboration, anticipating that the combined strengths of Biocytogen's BsADC discovery and Radiance's experienced team would accelerate the commercialization of this unique bispecific antibody drug conjugate.

Marc Lippman, MD, Chairman of the Board of Radiance, remarked on the promising preclinical data of the BsADC, emphasizing its potent anti-tumor activities across various indications. He looks forward to collaborating with Biocytogen to advance the product into clinical development for the benefit of patients.

 

Source: businesswire.com

Report Abuse